Coherus Oncology (NASDAQ:CHRS - Get Free Report) was upgraded by research analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research note issued on Sunday, Wall Street Zen reports.
Several other research analysts also recently commented on the stock. Weiss Ratings downgraded shares of Coherus Oncology from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Tuesday, November 10th. HC Wainwright started coverage on Coherus Oncology in a report on Thursday, October 29th. They set a "buy" rating for the company. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $11.00.
View Our Latest Stock Analysis on CHRS
Coherus Oncology Stock Performance
NASDAQ:CHRS opened at $0.37 on Friday. Coherus Oncology has a twelve month low of $0.36 and a twelve month high of $2.62. The company has a 50-day moving average of $0.97 and a 200-day moving average of $1.43. The firm has a market cap of $57.13 million, a price-to-earnings ratio of -0.38 and a beta of 1.03. The company has a current ratio of 1.51, a quick ratio of 1.45 and a debt-to-equity ratio of 2.08.
Coherus Oncology (NASDAQ:CHRS - Get Free Report) last posted its earnings results on Monday, November 9th. The biotechnology company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.03). The company had revenue of $14.27 million for the quarter, compared to the consensus estimate of $15.90 million. Coherus Oncology had a negative net margin of 253.43% and a negative return on equity of 274.46%. Analysts forecast that Coherus Oncology will post -0.86 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Large investors have recently added to or reduced their stakes in the business. BlackRock Inc. acquired a new position in Coherus Oncology during the 2nd quarter worth $16,805,000. GSA Capital Partners LLP purchased a new stake in shares of Coherus Oncology in the 2nd quarter valued at about $531,000. Cetera Investment Advisers acquired a new position in shares of Coherus Oncology in the first quarter valued at approximately $54,000. Jefferies Financial Group Inc. acquired a new position in shares of Coherus Oncology during the second quarter worth about $353,000. Finally, Empowered Funds LLC acquired a new position in shares of Coherus Oncology during the 3rd quarter worth $212,000. 72.82% of the stock is currently owned by institutional investors and hedge funds.
Trending Headlines about Coherus Oncology
These are some of the CHRS headlines that stood out recently:
- Negative Sentiment: HC Wainwright trimmed estimates for FY2026–FY2029, including FY2026 EPS from ($0.84) to ($0.89), FY2027 from ($0.63) to ($0.68), FY2028 from ($0.48) to ($0.54), and FY2029 from ($0.19) to ($0.26). It also lowered estimates for Q4 2026 and each quarter of 2027. These revisions point to greater expected losses in the near term and beyond. MarketBeat coverage
- Neutral Sentiment: Despite lowering its forecasts, HC Wainwright kept its Buy rating on CHRS. MarketBeat coverage
Coherus Oncology Company Profile
(
Get Free Report)
Coherus Oncology, formerly Coherus BioSciences, is a biopharmaceutical company focused on developing and commercializing cancer treatments. Its portfolio includes LOQTORZI (toripalimab-tpzi), an immune checkpoint inhibitor that targets PD-1 and is approved in the United States for certain patients with nasopharyngeal cancer. The company is also advancing a pipeline of investigational immuno-oncology medicines. Coherus historically built its business around biosimilar medicines before shifting its focus to oncology.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Coherus Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Coherus Oncology wasn't on the list.
While Coherus Oncology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.
This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.